Enzychem Lifesciences Corporation (KOSDAQ:183490)
South Korea
· Delayed Price · Currency is KRW 1,109.00
+28.00 (2.59%)
Apr 1, 2025, 3:30 PM KST
Enzychem Lifesciences Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2017 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2017 |
| Operating Revenue | 77,378 | 76,039 | 26,638 | 22,975 | 25,818 | Upgrade
|
| Other Revenue | -0 | - | -0 | - | - | Upgrade
|
| Revenue | 77,378 | 76,039 | 26,638 | 22,975 | 25,818 | Upgrade
|
| Revenue Growth (YoY) | 1.76% | 185.46% | 15.94% | -11.01% | -17.95% | Upgrade
|
| Cost of Revenue | 73,068 | 71,691 | 24,221 | 22,689 | 23,999 | Upgrade
|
| Gross Profit | 4,310 | 4,348 | 2,416 | 286.72 | 1,820 | Upgrade
|
| Selling, General & Admin | 12,215 | 12,017 | 9,834 | 10,859 | 7,697 | Upgrade
|
| Research & Development | 4,421 | 5,434 | 6,558 | 9,501 | 12,865 | Upgrade
|
| Operating Expenses | 20,686 | 19,081 | 17,078 | 21,040 | 20,927 | Upgrade
|
| Operating Income | -16,376 | -14,733 | -14,662 | -20,754 | -19,107 | Upgrade
|
| Interest Expense | -238.7 | -620.09 | -10,030 | -9,508 | -1,430 | Upgrade
|
| Interest & Investment Income | 5,207 | 5,489 | 3,976 | 963.71 | 552.02 | Upgrade
|
| Earnings From Equity Investments | -2,176 | 26.87 | -13.64 | -445.14 | -378.53 | Upgrade
|
| Currency Exchange Gain (Loss) | 244.33 | -34.38 | -164.71 | -60.59 | 28.7 | Upgrade
|
| Other Non Operating Income (Expenses) | -6,660 | 41.19 | -7.09 | 292.36 | 1,422 | Upgrade
|
| EBT Excluding Unusual Items | -20,000 | -9,830 | -20,901 | -29,512 | -18,913 | Upgrade
|
| Gain (Loss) on Sale of Investments | -1,938 | 3.65 | 3.57 | 4.39 | -258.53 | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.45 | -19.5 | 8.12 | -13.27 | - | Upgrade
|
| Asset Writedown | -145.56 | -32.74 | -4,692 | 16.05 | -60.09 | Upgrade
|
| Pretax Income | -22,084 | -9,879 | -25,581 | -29,504 | -19,232 | Upgrade
|
| Income Tax Expense | 3.12 | -476.3 | -488.27 | -1,640 | -1,725 | Upgrade
|
| Earnings From Continuing Operations | -22,088 | -9,403 | -25,093 | -27,865 | -17,507 | Upgrade
|
| Minority Interest in Earnings | -19.01 | 76.24 | - | - | - | Upgrade
|
| Net Income | -22,107 | -9,326 | -25,093 | -27,865 | -17,507 | Upgrade
|
| Preferred Dividends & Other Adjustments | - | - | -159.59 | -941.77 | -63.66 | Upgrade
|
| Net Income to Common | -22,107 | -9,326 | -24,934 | -26,923 | -17,443 | Upgrade
|
| Shares Outstanding (Basic) | 82 | 85 | 79 | 50 | 49 | Upgrade
|
| Shares Outstanding (Diluted) | 82 | 85 | 79 | 50 | 49 | Upgrade
|
| Shares Change (YoY) | -3.43% | 7.57% | 56.10% | 3.93% | 3.53% | Upgrade
|
| EPS (Basic) | -270.00 | -110.00 | -316.34 | -533.20 | -359.04 | Upgrade
|
| EPS (Diluted) | -270.00 | -110.00 | -316.34 | -533.20 | -359.04 | Upgrade
|
| Free Cash Flow | -897.74 | -12,506 | -22,277 | -24,407 | -16,857 | Upgrade
|
| Free Cash Flow Per Share | -10.96 | -147.50 | -282.63 | -483.37 | -346.96 | Upgrade
|
| Gross Margin | 5.57% | 5.72% | 9.07% | 1.25% | 7.05% | Upgrade
|
| Operating Margin | -21.16% | -19.38% | -55.04% | -90.33% | -74.01% | Upgrade
|
| Profit Margin | -28.57% | -12.26% | -93.60% | -117.18% | -67.56% | Upgrade
|
| Free Cash Flow Margin | -1.16% | -16.45% | -83.63% | -106.23% | -65.29% | Upgrade
|
| EBITDA | -12,918 | -11,221 | -12,273 | -18,643 | -17,072 | Upgrade
|
| EBITDA Margin | -16.69% | -14.76% | -46.07% | -81.14% | -66.12% | Upgrade
|
| D&A For EBITDA | 3,458 | 3,512 | 2,389 | 2,111 | 2,036 | Upgrade
|
| EBIT | -16,376 | -14,733 | -14,662 | -20,754 | -19,107 | Upgrade
|
| EBIT Margin | -21.16% | -19.38% | -55.04% | -90.33% | -74.01% | Upgrade
|
| Advertising Expenses | 520.5 | 299.56 | 456.54 | 443.63 | 279.89 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.